Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer

By Xu N.   Shen P.   Zhang X.   Yu L.   Bao H.   Shi G.   Huang S.   Chen J.   Mou H.   Fang W.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite

Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer - a phase II trial

By Laack E.   Mende T.   Benk J.   Chemaissani A.   Scholtze J.   Lorenz C.   Niestroy A.   Dalhoff K.   Muller T.   Walter T.   Durk H.   Edler L.   Hossfeld D.K.  

European Journal of Cancer, Vol. 37, Iss. 5, 2001-03 ,pp. : 583-590

Elsevier

Access to resources Recommend Favorite

Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations

By Grossi F.  

memo - Magazine of European Medical Oncology, Vol. 1, Iss. 1, 2008-03 ,pp. : 13-16

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo   Cappuzzo Federico  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial

By Helsing M.   Bergman B.   Thaning L.   Hero U.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 1036-1044

Elsevier

Access to resources Recommend Favorite